Multiple myeloma (MM) is a malignant proliferation of plasma cells that usually invades the bone marrow, but involves other areas as well. One kind of thoracic involvement is pleural effusion. In 6% of patients with myeloma, pleural effusions developed (myelomatous and non myelomatous).1 Myelomatous pleural effusions are rare, with approximately 80 cases reported worldwide.2,3 We present 5 cases of patients with MM who developed myelomatous pleural effusions (Table 1). We analyzed the clinical presentation and outcome of this association.

**CASE 1**
A 74-year-old male patient without medical history was admitted to our department in June 2007 for diffuse bone pain. Low back pain had started a few months before and progressed to severe disability. He had lost more than 10 kg of body weight over the previous three months. Physical examination was normal. Laboratory studies revealed a normal cell blood count and blood chemistry values, including serum calcium, within normal ranges. Serum electrophoresis revealed a gamma M component, and serum immune electrophoresis demonstrated IgA monoclonal protein. Radiographic examination showed osteolytic punched-out lesions in the skull and pelvis. Bone marrow aspiration revealed 57% of dystrophic plasmocytosis. The diagnosis of multiple myeloma stage III was accepted. Melphalan-prednisone chemotherapy was started. Two months after the administration of the final course of chemotherapy, the patient was readmitted for chest pain and dry cough without fever or sputum production. Chest X-ray showed pleural effusion. Chest CT scan revealed a scalloped aspect of the pleura with bilateral effusion, thus leading to the conclusion of myelomatous pleural effusion. Unfortunately, neither thoracocentesis nor pleural biopsy were made. The patient left the hospital against medical advice and was lost to follow-up.

**CASE 2**
A 62-year-old male patient, with a medical history of non-insulin-dependent diabetes, was hospitalized in 2001 for bone pain with unencrypted emaciation. He reported a three-month history of dull right lower chest pain which was not made worse by coughing or deep inspiration. No hemoptysis or fever was present. Physical examination revealed dullness and decreased breath sound at the base of the right lung. Laboratory data showed an erythrocyte sedimentation rate of 30 at the first hour, a normal range of serum calcium, hy-
pleural myelomatous in MM

Case 1
A 74-year-old male was admitted with a history of back pain and emaciation. Clinical examination revealed muffled lung sounds on the right chest. Chest X-ray showed pleural effusion. Thoracocentesis yielded exudative effusion. Cytology revealed an increase in atypical plasma cells. Immune fixation of proteins in pleural fluid showed monoclonal lambda light chains. Pleural biopsy confirmed the plasmocyte infiltration. The patient was diagnosed with light chain lambda type MM and underwent polychemotherapy with melphalan and prednisone. The pleural effusion improved with chemotherapy.

Table 1. Characteristics of our patients with pleural involvement by multiple myeloma.

| Characteristic | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---------------|--------|--------|--------|--------|--------|
| Age/Gender    | 74/Male| 62/Male| 62/Female| 52/Male| 55/Male|
| Inaugural symptoms | Back pain | Emaciation | Bone pain | Dyspnea | Back pain |
| Monoclonal gamma globulin type | Ig A | lambda light chain | Ig G kappa | Ig G kappa | Ig G lambda |
| Multiple myeloma stage | IIIa | IIIa | IIIa | IIa | IIa |
| Myelomatous pleural effusion delay | 2 months | Inaugural | 5 months | Inaugural | Inaugural |
| Thoracocentesis findings | Not performed | Exudative effusion and plasmocytes in pleural fluid | Exudative effusion | Exudative effusion | Exudative effusion |
| Treatment | Melphalan Prednisone | Vincristine Adriamycin Dexamethasone | Melphalan Cyclophosphamide Dexamethasone | Vincristine Adriamycin Dexamethasone | Melphalan Prednisone |
| Outcome | Lost of sight | Dead | Dead | Dead | Dead |
and dry cough. He had been on a trial antibiotic treatment, which did not alleviate his complaints. Physical examination was normal apart from decreased breath sounds and percussion dullness over the right lung. The only abnormality in blood cell count analysis was mild leukocytosis. Blood chemistry including calcium level was within normal range except a gamma M component on serum electrophoresis and IgG kappa light chain on immune serum electrophoresis. Standard radiographs showed osteolytic punched-out lesions in the skull, and a right basal pleural effusion. Bone marrow aspiration revealed 52% dystrophic plasmocytosis. Thoracocentesis yielded exudative effusion with multiple atypical plasmocytes. Immune fixation of proteins in pleural fluid showed monoclonal IgG kappa light chain. Pleural biopsy confirmed the plasmocyte infiltration. The patient received three courses of polychemotherapy with vincristine, adriamycin, and dexamethasone, but no response was observed and his disease worsened. He died 4 months later of acute respiratory distress.

**CASE 5**

A 55-year-old male patient presented to our department complaining of shortness of breath and low back pain. On physical examination, blood pressure was 100/60, heart rate 96/min, respiratory rate 24/min, and temperature 39°C. Examination of the respiratory system revealed decreased breath sounds and percussion dullness over the left lung. Blood chemistry including calcium level was within normal range except a gamma M component on serum electrophoresis and IgG lambda light chain on immune serum electrophoresis. Standard radiographs showed osteolytic punched-out lesions in the skull, and a left basal pleural effusion. Bone marrow aspiration revealed a dystrophic plasmocytosis. Thoracocentesis yielded exudative effusion with atypical plasmocytes. Immune fixation of proteins in pleural fluid showed monoclonal IgG lambda light chains. Pleural biopsy confirmed the plasmocyte infiltration. Melphalan-prednisone chemotherapy was started. The patient improved initially but died a few months later of septicemia.

**DISCUSSION**

Pleural effusion occurs in 6% patients with MM. The etiology is multifactorial, and effusions due to pleural myelomatous involvement are rare, occurring in less than 1% of the cases. Common causes of pleural effusions in MM include congestive heart failure due to hyperviscosity or amyloidosis, renal failure, pulmonary embolism due to a hypercoagulable state or plasma embolization, a secondary neoplasm such as mesothelioma, infections due to immunosuppression (pneumonia, tuberculosis, AIDS, other viral illnesses), and chylothorax or bleeding. Several criteria must be fulfilled to assert the myelomatous origin of the pleural effusion. The presence of plasma cells in pleural fluid is a fundamental criterion and the use of Wright stain enhances the identification of these cells. The detection in pleural fluid of monoclonal immunoglobulin identical to that of serum is not an essential criterion; it does not allow its malignant nature to be asserted because it can be produced locally. Pleural biopsy may reveal a plasma cell infiltration but it is not necessary for diagnosis as, due to discontinuous myeloma lesions, it can be noncontributory. To our knowledge, respectively 32 cases and 47 cases of myelomatous pleural effusion have been reported in the English and Japanese literature. Our experience with 235 myeloma patients involved 5 cases (3.6%), inaugural in three cases, IgG type MM in three cases, IgA type in one case, and lambda light chain type in one case. In the literature reporting myelomatous pleural effusions, 80% of them were due to IgA, perhaps as a result of its major tendency to invade extrasosseous structures. However, Meoli et al, in a review of the literature, reported a predominance of IgG myeloma. Pleural effusions due to plasma cell infiltration are rare and may result from extension of adjacent subcutaneous plasmocytomas, skeletal plasmocytomas, adjacent parenchymal plasmocytomas into the pleural space, or direct implantation into the pleura. Therefore, it was suggested that the major determining factor in the development of myelomatous effusion is the production of large quantities of immunoglobulin by malignant plasma cells in or near the pleura, which raise the colloid osmotic pressure of the fluid to such a level that normal absorption cannot take place. Kazuhiko et al were interested in chromosomal abnormalities in a case of MM with myelomatous pleural involvement.
and concluded with a variety of chromosomal abnormalities; a translocation involving the immunoglobulin heavy chain (Ig H) region at chromosome region 14q32 which is regularly involved in human B cell malignancies and may upregulate existing oncogenes or create new hybrid genes with transforming properties. 14q32 was detected in 74% of patients with MM, by fluorescence in situ hybridization and it is one of the factors related to poor prognosis. These translocations are found in the earliest stage of the disease, suggesting that they are an early and possibly initiating event in the disease development. The detection of genetic changes is important, not only because of their associations with clinical prognosis, but also because they can be used as measurable targets for response to treatment. Treatment of myelomatous pleural effusion is not codified and uses systemic chemotherapy, sometimes associated with radiotherapy in case of local invasion, or local treatment by intrapleural injection of methylprednisolone, adriamycin and interferon. The pleural talc pleurodesis may be necessary in some cases of recurrent pleural effusions. Myelomatous pleural effusion is characterized by its recurrence and inexhaustible nature. Its occurrence is a factor of poor prognosis and median survival does not appear to exceed four months from the date of discovery, all treatments being combined. However, favorable outcomes have been reported, with a survival exceeding nine months.

CONCLUSION
Malignant effusions in myeloma patients are associated with poor prognosis. Affected patients are usually resistant to treatment and often relapse in spite of aggressive chemotherapy necessitating pleurodesis. Despite the wide choice of available therapeutic measures our patients died.

REFERENCES
1. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ; Southwest Oncology Group. Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003;122:441-50.
2. Rodriguez JN, Pereira A, Martinez JC, Conde J, Pujol E. Pleural effusion in multiple myeloma. Chest 1994; 105:622-4.
3. Taro, Melikoglu A, Tahaoglu C et al. Pleural effusion as the first sign of multiple myeloma. Tuberk Toraks 2008;56:439-42.
4. Uskil BT, Türker H, Emre Turan F, Unal Bayraktar O, Melikoglu A, Tahaoğlu C et al. Pleural effusion as the first sign of multiple myeloma. Tuber Toraks 2008;56:439-42.
5. Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D. Pleural effusions in hematologic malignancies. Chest 2004;125:1546-55.
6. Neuman G, Denekamp Y. Dyspnea and pleural effusion as presenting clinical manifestations of multiple myeloma. Isr Med Assoc J 2009;11:118-9.
7. Lau LG, Cheng WJ, Tan LH, Liu TC. Malignant pleural effusion in a patient with multiple myeloma. Diagn Cytopathol 2005;32:171-2.
8. Kapadia SB. Cytological diagnosis of malignant pleural effusion in myeloma. Arch Pathol Lab Med 1977;101:534-5.
9. Quinquenel ML, Moualla M, Le Coz A, Gacouin A, Lena H, Leblay R et al. Pleural involvement in myeloma. About two cases. Rev Mal Respir 1995;12:173-4.
10. Sasser RL, Yam LT, Li CY. Myeloma with involvement of the serous cavities. Cytologic and immunohistochimical diagnosis and literature review. Acta cytol 1990;34:479-85.
11. Okazaki H, Himori T, Asoh N et al. An autopsy case of Bence-Jones type myeloma associated with massive extramedullary tumors in the thorax and kidney. Pleural effusion and renal failure. Intern Med 1989;28:587.
12. Meoli A, Willse S, Fiorella R. Myelomatous pleural effusion. South Med J 1997;90:65-8.
13. Raci-Wetherbee E, Dincer HE. IgH myeloma presenting as a large mediastinal mass and pleural effusion. J Bronchology Interv Pulm 2012;18:85-7.
14. Caroline C, Louis CW. Response of myelomatous pleural effusion due to chemotherapy. Chest 1981;80:765-6.
15. Kazuhiko N, Haruka I, Daisuke N et al. IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion. Ann Hematol 2008;87:587-9.
16. Auzet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MA, Harousseau JL et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and presentation. Blood 2002;99:2185-91.
17. Elloumi M, Frihka M, Masmoudi H, Mseddi S, Ben Ayed M, Bouaziz M et al. Plasmacytic pleural effusion disclosing a multiple myeloma. Rev Mal Respir 2000;17:495-7.
18. Ben Ghorbel I, Ksontini I, Houman MH, Hauet S, Lamloum M, Rih M et al. Bilateral myelomatous pleural effusion. A case report. Rev Med Interne 2001;22:1134-5.
19. Xu XL, Shen YH, Shen Q, Zhou YJ. A case of bilateral pleural effusion as the first sign of multiple myeloma. Eur J Med Res 2013;20:18-7.